Skip to content

Myocarditis Treatment Trial

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00000524
Enrollment
Unknown
Registered
1999-10-28
Start date
1986-07-31
Completion date
1994-03-31
Last updated
2023-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Diseases, Heart Diseases, Myocarditis

Brief summary

To determine whether immunosuppressive treatment improved cardiac function in patients with biopsy-proven myocarditis.

Detailed description

BACKGROUND: Heart failure due to myocarditis can be a devastating illness. At the same time, immunosuppressive therapy is associated with considerable risks of untoward side effects. Clinicians did not know whether, under what circumstances, or in what form, this hazardous treatment should be used in such critically ill patients. In addition, if immunosuppressive therapy was of benefit, then endomyocardial biopsy in patients suspected of having myocarditis was a justified procedure. The trial also provided information concerning the side effects of immuno-suppressive therapy in such patients. DESIGN NARRATIVE: Patients were randomized into two treatment arms consisting of conventional therapy alone for congestive heart failure or combined with a twenty-four week regimen of immunosuppressive therapy. Immunosuppressive therapy consisted of prednisone with either cyclosporine or azathioprine. The primary outcome measure was a change in the left ventricular ejection fraction at twenty-eight weeks. Secondary endpoints included survival, failures of therapy, requirements for conventional therapy, assessments of symptoms, myocardial histology, and arrhythmias. The study completion date listed in this record was obtained from the Query/View/Report (QVR) System.

Interventions

DRUGcyclosporine
DRUGprednisone

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)
CollaboratorNIH
University of Utah
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

Men and women, 18 years of age or older, with left ventricular failure and biopsy-documented myocarditis.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026